Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Manfred Schwab
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6691-2



Is an antiangiogenesis agent developed by Regeneron and the Sanofi-Aventis Group; is a fusion protein specifically designed to bind as a soluble decoy receptor all forms of Vascular Endothelial Growth Factor-A (VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. Disruption of the binding of VEGFs to their cell receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately lead to tumor regression. In addition, Aflibercept binds Placenta Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. Breast Cancer Targeted Therapy



Breast Cancer Blood Vessel Cancer Research Fusion Protein Cell Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.German Cancer Research Center (DKFZ)HeidelbergGermany